Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics

Table 1 Comparison of oncogenes and tumor suppressor genes (TSGs) on lung SqCC and ADC tumors

Gene	SqCC		ADC		Type
Gene	mRNA, microRNA, and DNA sequencing [12]	Proteomics glycoproteomics	mRNA, microRNA, and DNA sequencing [13]	Proteomics glycoproteomics	Type
TP53	+	+	+	NE	Oncogene
KRAS	+	−		−	Oncogene
KEAP1	+	NC	+	ND	Oncogene
STK11	+	ND		−	TSG
EGFR	+	+		+	Oncogene
NF1	+	ND		ND	TSG
BRAF	+	NC		NC	Oncogene
SETD2	+	ND		ND	TSG
RBM10	+	NC		NC	TSG
MGA	+	ND		ND	TSG
MET	+	+		+	Oncogene
ARID1A	+	NC		NC	TSG
PIK3CA	+	Y−	+	−	Oncogene
SMARCA4	+	NC		−	TSG
RB1	+	NC	+	NC	Oncogene
CDKN2A	+	+	+	+	TSG
U2AF1	+	+		Y−	Oncogene
RIT1	+	−		NC	TSG
NOTCH1		ND	+	−	TSG
PTEN		NC	+	−	TSG
HLA-A*		+	+	+	Oncogene
NFE2L2		ND	+	ND	Oncogene
MLL2		ND	+	ND	TSG
FHIT		NC		NC	Oncogene
MST1		NC		−	TSG
BAD		NC		NC	Oncogene
RXR		+		ND	Oncogene
NFκBIA		−		−	TSG

The activation or inhibition is based on quantitative data from proteins and glycoproteins. The analysis was performed using Ingenuity Pathway Analysis (IPA). NC no change, ND not detected, NE no effect, “+” activation or upregulation, “−” inhibition or downregulation, “*” only detected in glycoproteins by SPEG. Gene mutation is compared with studies using mRNA, microRNA, and DNA sequencing on ADC [12] and SqCC [13]

ISSN: 1559-0275